This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Chromosomal rearrangement involving 11q23 locus in chronic myelogenous leukemia: a rare phenomenon frequently associated with disease progression and poor prognosis
Journal of Hematology & Oncology Open Access 08 April 2015
-
Integrative analysis of high-throughput RNAi screen data identifies the FER and CRKL tyrosine kinases as new regulators of the mitogenic ERK-dependent pathways in transformed cells
BMC Genomics Open Access 23 December 2014
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Cortes J, O'Dwyer ME . Clonal evolution in chronic myelogenous leukemia. Hematol Oncol Clin N Am 2004; 18: 671–684.
Fayad L, Kantarjian H, O'Brien S, Seong D, Albitar M, Keating M et al. Emergence of new clonal abnormalities following interferon-alpha induced complete cytogenetic response in patients with chronic myeloid leukemia: report of three cases. Leukemia 1997; 11: 767–771.
Medina J, Kantarjian H, Talpaz M, O'Brien S, Garcia-Manero G, Giles F et al. Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase. Cancer 2003; 98: 1905–1911.
Kovitz C, Kantarjian H, Garcia-Manero G, Abruzzo LV, Cortes J . Myelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemia. Blood 2006; 108: 2811–2813.
Loriaux M, Deininger M . Clonal cytogenetic abnormalities in Philadelphia chromosome negative cells in chronic myeloid leukemia patients treated with imatinib. Leuk Lymphoma 2004; 45: 2197–2203.
Jabbour E, Kantarjian H, Abruzzo L, Giles F, Rios MB, Cortes J . Chromosomal abnormalities in Philadelphia chromosome (Ph)-negative metaphases appearing during novel tyrosine kinase inhibitors (NTKI) therapy in patients (pts) with chronic myeloid leukemia (CML) after imatinib-failure. Blood 2006; 108, Abstract 2115.
Casali M, Truglio F, Milone G, Di Raimondo F, Parrinello G, Maserati E et al. Trisomy 8 in Philadelphia chromosome (Ph1)-negative cells in the course of Ph1-positive chronic myelocytic leukemia. Genes Chromosomes Cancer 1992; 4: 269–270.
Royer-Pokora B, Hildebrandt B, Redmann A, Herold C, Kronenwett R, Haas R et al. Simultaneous occurrence of a t(9;22) (Ph) with a t(2;11) in a patient with CML and emergence of a new clone with the t(2;11) alone after imatinib mesylate treatment. Leukemia 2003; 17: 807–810.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Quintás-Cardama, A., Kantarjian, H., Abruzzo, L. et al. Extramedullary BCR-ABL1-negative myeloid leukemia in a patient with chronic myeloid leukemia and synchronous cytogenetic abnormalities in Philadelphia-positive and -negative clones during imatinib therapy. Leukemia 21, 2394–2396 (2007). https://doi.org/10.1038/sj.leu.2404865
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2404865
This article is cited by
-
Philadelphia chromosome-negative acute promyelocytic leukemia manifesting after long-term imatinib treatment for chronic myeloid leukemia: a case report and literature review
Annals of Hematology (2018)
-
Chromosomal rearrangement involving 11q23 locus in chronic myelogenous leukemia: a rare phenomenon frequently associated with disease progression and poor prognosis
Journal of Hematology & Oncology (2015)
-
Integrative analysis of high-throughput RNAi screen data identifies the FER and CRKL tyrosine kinases as new regulators of the mitogenic ERK-dependent pathways in transformed cells
BMC Genomics (2014)